Last reviewed · How we verify
NCT04891536: CRIOAND2021
Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy
NA trial testing Salvage cryoablation of the prostate (SCAP) in Prostate Cancer in 100 participants. Currently enrolling.
1 May 2025
Quick facts
| Lead sponsor | Ignacio Puche Sanz |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 May 2021 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 May 2026 |
| Sites | 2 locations across Spain |
Drugs / interventions tested
- Salvage cryoablation of the prostate (SCAP)
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
- Cryotherapy — all drugs for Cryotherapy →
- Recurrent Prostate Cancer — all drugs for Recurrent Prostate Cancer →
Sponsor
Ignacio Puche Sanz
Who can join
Adults 18 to 90, male only, with Prostate Cancer or Cryotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this project is to establish a shared comprehensive and systematic protocol for a multicenter prospective registry of patients undergoing salvage cryoablation of the prostate (SCAP). Our study hypothesis is that SCAP constitutes an effective and safe approach to treat local prostate cancer recurrence after brachytherapy or external beam radiation therapy (EBRT).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Status of Cryoablation in Prostate Cancer Management.
Karwacki J, Kiełbasa J, Szczepaniak Z, Zagórski K, et al · · 2025 · PMID 40620664 · DOI 10.1177/11795549251350830
Verify or expand the search:
- PubMed search for NCT04891536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other Ignacio Puche Sanz trials
Trials by the same sponsor.
- NCT05530395 — BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04891536 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ignacio Puche Sanz
- Last refreshed: 18 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04891536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing